Table 1.
Characteristics of Included Studies in the Meta-Analysis.
| Author | Year | Country | Age (Mean or Median) |
Se X(% female) |
Total Cases | Micro-Invasive/ Invasive Cases (%) |
Positive Expression In Microinvasive/INVASIVE Cases (%) |
Marker | Positive ihc Espression (%) |
Her2 Amplificatin Status (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Aoyagi, et al. | 2008 | Japan | 70.6 | 34.7 | 23 | 6/23 (26) |
4/6 (66.6) | HER2 | F: 7/8 (87.5) M: 10/15 (66.6) |
N/A |
| Bianco, et al. | 2006 | USA | 75 | 100 | 15 | N/A | N/A | HER2 | 6/15 (40) | 1/15 (7) |
| Brummer, et al. |
2004 | Germany | N/A | 100 | 10 | 2/10 (20) |
2/2 100 |
HER2 | 8/10 (80) | N/A |
| Diaz de Leon, et al. | 2000 | USA | 64.5 | 82 | 28 | N/A | N/A | AR PR ER |
F: 12/23 (52.2) M: 3/5 (60) 0/28 0/28 |
|
| Fujimoto, et al. | 2000 | Japan | 67 | 26.6 | 30 | 13/30 (43.3) |
9/13 (26.6) | AR | F: 8/8 (100) M: 16/22 (72.7) |
|
| Garganese, et al. | 2019 | Italy | 67 | 100 | 41 | 11/41 (26.8) |
HER2 4/11 (36.3) AR 10/11 (90.9) PR 2/11 (18) ER 8/11 (72.7) |
HER2 AR PR ER |
10/41 (24.4) 33/41 (80.5) 9/41 (22) 29/41 (70.7) |
10/41 (24.4) |
| Gatalica, et al. | 2020 | USA | 61 | 72.2 | 18 | 15/18 (83.3) |
AR 9/15(60) ER (4)/15 (26.6) |
AR ER |
F: 9/13 (69.2) M: 3/5 (60) F: 2/13 (15.3) M: 2/5 (40) |
|
| Hanna, et al. | 2003 | Canada | N/A | 100 | 20 | N/A | N/A | HER2 | 1/20 (5) | 0/19 |
| Hikita, et al. | 2012 | Japan | 70.47 | 64.70 | 17 | 23.5 | ER 0/2 PR 0/2 HER2 8/8 4/4(100) |
HER2 | F: 9/11 (81.8) M: 3/6 (50) |
0/8 |
| Horn, et al. | 2008 | Germany | N/A | 100 | 8 | N/A | N/A | HER2 ER PR |
8/8 (100) 1/8 (12.5) 1/8 (12.5) |
N/A |
| Inoguchi, et al. | 2006 | Japan | 71.7 | 17.6 | 34 | N/A | N/A | AR | F: 1/6 (16.6) M: 14/23 (60.8) |
|
| Kasashima, et al. | 2010 | Japan | 71.5 | 44.8 | 58 | 16/58 (27.5) |
9/16 (56.2) |
AR | F: 12/26 (46) M: 21/32 (65.6) |
|
| Liegl, et al. | 2005 | Germany | N/A | 100 | 23 | N/A | N/A | HER2 AR PR ER |
12/23 (52) 18/23 (78) 0/23 (0) 1/23 (4) |
N/A |
| Liu, et al. | 2009 | USA | 69 | 71.4 | 14 | N/A | N/A | HER2 | 5/14 (35.7) | N/A |
| Lu, et al. | 2018 | China | 63 | 0 | 11 | N/A | N/A | HER2 | 3/11 (27.2) | 2 (FISH+) + 1(genetic heterogeneity)/11 |
| Masuguchi, et al. | 2011 | Japan | N/A | 41.9 | 31 | 11/31 (35.4) |
10/11 (90.9) |
HER-2 | F: 7/13 (53.8) M: 12/18 (66.6) |
N/A |
| Miyamoto, et al. | 2010 | Japan | 74 | 43.7 | 32 | 19/32 (59.3) |
13/19 (68) |
HER2 | F: 7/14 (50) M: 13/18 (72) |
2/5 (40) |
| Morbeck, et al. | 2016 | Brazil | 66.8 | 100 | 11 | 2/11 (18) |
2/2 (100) |
HER2 | 6/11 (54.5) | 2/6 (33.3) |
| Ogawa, et al. | 2005 | Japan | 68.5 | 14.7 | 34 | 16/34 (47) 18/34 (52.9) |
5/18 (27.7) | HER2 | F: 1/5 (20) M: 6/29 (20.6) |
3/7 (42.8) |
| Plaza, et al. | 2009 | USA | 66 | 70.2 | 47 | 2/47 (4.2) |
0/2 (0) |
HER2 | F: 14/33 (42.4) M: 1/14 (7) |
N/A |
| Reich, et al. | 2005 | Austria | 63 | 100 | 6 | N/A | N/A | HER2 | 4/6 (66.6) | 4/6 (66.6) |
| Richter, et al. | 2010 | USA | 68.5 | 100 | 33/39 * | 7/33 (21) |
5/7 (71) |
HER2 | 19/33 (57.5) |
N/A |
| Sekiguchi, et al. | 2020 | Japan | 71 | 50 | 4 | N/A | N/A | HER2 | F: 2/2 (100) M: 2/2 (100) |
2 amplified 2 polysomic |
| Tanaka, et al. | 2016 | Japan | 72 | 15.3 | 26 | 26/26 (100) |
6/26 (23.07) |
HER2 | F: 2/4 (50%) M: 4/22 (18) |
5/6 (83.3) |
| Tanaka, et al. | 2013 | Japan | 71.1 | 33.6 | 104 | 73/104 (36.5) |
10/73 (13.7) |
HER2 | F: 5/35 (14.2) M: 7/69 (10) |
12/16 (75) |
| Tanskanen, et al. | 2003 | Finland | 65.47 | 60.8 | 23 | 3/23 (13.04) |
1/3 (33.3) |
HER2 | F: 12/23 (52) M: 4/9 (44.44) |
10/23 (43.47) |
| Zhang, et al. | 2015 | China | 61.5 | 0 | 2 | 1/2 (50) |
1/2 (50) |
HER2 | 1/2 (50) | N/A |
* Tissue specimens available for Her-2/neu testing.